Italian biotech company EryDel SPA has raised €6.5m ($32.4m) through venture financing in order to enhance its international development and to complete the Attest , a registrational phase three clinical trial.
Graziano Seghezzi, the managing partner of Sofinnova Partners, has been inducted as director of the EryDel’s board.
EryDel intends to use proceeds for conducting the clinical trial across Europe, Asia, Australia, and in the US.
The US-based biotechnology company proposes to use funds for targeting protein stability using small molecule therapeutics.
US-based Sangamo Therapeutics Inc plans to raise funds for supporting gene therapy, genome editing, cell therapy and gene regulation product candidates and research programmes.
The company has announced to issue shares of its common stock in an underwritten public offering to raise $200m for the same. The underwriters will be granted a 30-day option to buy additional shares worth $30m.
Sangamo Therapeutics expects to raise net proceeds of $187.7m through the offering.
The company also plans to use part of the proceeds for manufacturing facilities and other business development activities.
Merrill Lynch , Pierce, Fenner & Smith Inc, JP Morgan Securities LLC and Cowen and Company LLC have been appointed as joint book-running managers, while Cooley LLP has been appointed as legal advisor for the transaction.
Revolution Medicines proposes to use the proceeds for supporting its current research and development (R&D) programmes, and general corporate purposes.
UK-based ADC Biotechnology Ltd has raised £1.14m ($1.59m) through a private placement, which has been subscribed to by Downing LLP.
ADC Biotechnology uses the proceeds for reinforcing its business in the US and for developing new antibody-drug conjugates (ADC) manufacturing approach.
Canadian company Spectral Medical Inc has completed the issuance of 17,694,661 units in a private placement.
The units comprise one share and one-half of a share purchase warrant. The holders are entitled to acquire one additional share for each full warrant at an exercise price of C$0.45 ($0.35) a share within three years of the issue date.
The company has raised gross proceeds of C$5.3m ($4.14m) through the placement.
Proceeds are intended to be used for the clinical development of PMX cartridge and for FDA regulatory approval of the same. Part of the proceeds will also be used for general corporate purposes.